AnukritiAI
Anukriti AIOpen the platformRequest a briefing
← Anukriti AI

Where we're headed

From research prototype to clinical-grade validation.

Five phases, staged honestly. The first three are complete and live. The fourth is new and early. The fifth — clinical-grade validation — is in progress.

Deterministic trial wedge Completed · Live

Three shipped workflows with auditable call statuses and CPIC + PharmVar provenance.

  • Clopidogrel / CYP2C19
  • Warfarin / CYP2C9 + VKORC1 + CYP4F2
  • Simvastatin / SLCO1B1

Reviewer trust layer Completed · Live

Benchmarks, confidence calibration, reproducibility packs, evidence mapping, and reviewer reports.

  • Evidence Sufficiency Layer with named refusals
  • 12 R-rules · 10 V-rules · 9 U-rules
  • 3 bias-detection kinds

Pilot operations Completed · Live

The production API and a public, zero-auth demo surface are running, with real 1000 Genomes sample mode.

  • Production API on Azure Container Apps + MongoDB Atlas
  • Deployed engine: anukriti-pgx-core 0.11.0, reported by the API itself
  • Public zero-auth demo, 1000 Genomes sample mode
  • Per-cohort outcome distributions
  • Shareable run permalinks

Trial-planning surface New · Early

A cohort-level question for a trial sponsor: given the genetic architecture of two cohorts for one enzyme, at what fraction metabolised does a drug cross into a dosing liability. It takes no patient, no genotype and no VCF, and returns no dose.

  • Trial-planning tool at /tools/fm-star, over four API routes
  • Four named refusals: U-FM, U-PREV, U-CV, U-MODULE
  • Of three audited probes, only S-warfarin (CYP2C9) passes the extraction audit
  • Omeprazole and metoprolol therefore give upper bounds, not estimates
  • Early work — not validated, and not offered as a clinical conclusion

Clinical-grade validation In progress

Deeper concordance benchmarking and an ancestry-specific evidence pack.

  • PharmCAT concordance benchmark
  • BCHE / Vysya founder-community wedge (Kerdoncuff 2025)
  • CYP2D6 CNV calling via Cyrius
  • Full AFR-specific evidence pack
  • Partnership outreach: PharmVar, LASI-DAD, GenomeIndia